388
Zia-ur-Rehman et al. / Inorganica Chimica Acta 376 (2011) 381–388
with those that are usually observed for most octahedral
complexes [35,36]. An analysis of the crystal packing for this
compound (Fig. 4) shows that the molecules are held together by
S2CꢀꢀꢀH and CH3OꢀꢀꢀH interactions, that are 0.1 Å less than
van-der-Waals contacts of the connected atoms. No secondary
SnꢀꢀꢀS interactions are noted, as is usually the case for monoclinic
forms of diorganotin(IV) dithiocarboxylates [12].
complexes 4 and 6 with a distorted square pyramidal and a
skew-trapezoidal geometry, respectively.
The square-pyramidal geometry is unique because this kind of
geometry is not previously reported in the literature for triphenyl-
tin(IV) derivatives. The antimicrobial activities of the complexes
are, in broad terms, excellent and far exceed the level for the li-
gand-salt. The influence of the tin is clearly visible in the antibac-
terial activity. Such a study will be helpful in designing novel
antifungal metal-based drugs.
3.4. Antibacterial and antifungal activities
Acknowledgements
The antibacterial activities of ligand-salt and complexes were
tested by agar well diffusion method [21] against five different
strains of bacteria are shown in Table 7. The ligand-salt and the
complexes exhibited good activities against the test bacteria. The
organotin derivatives are more active than is the ligand-salt. i.e.,
complexation increases the bactericidal potency. This situation
can be understood in term of chelation theory, which states that
the polarity of the metal ion is reduced upon complexation, which
results in an increase the lipophilicity of the metal complexes, thus
facilitating their ability to cross the cell membrane more easily
[37]. Among the triorganotin(IV) derivatives examined here, the
bactericidal activities of complexes 1, 3 and 4 are fairly good. Com-
plex 1 exhibited lower activity against S. aureus and Streptococcus.
Complex 2 is the least active, while complex 3 is active against all
the bacterial strains. In general, the chlorodiorganotin(IV) com-
plexes are more active than are their counterparts without chloride
substituents. The most probable reason is that chloro group might
decrease the hydrophobic character of the complexes, rendering
them biologically active [38]. In order to check the idea whether
the precursors, organotin(IV) chloride, are more or less active then
the corresponding organotin(IV) derivatives of the ligand; we se-
lect (C6H5)3SnCl, (CH3)3SnCl, (CH3)2SnCl2 and (C2H5)2SnCl2, and
screened them against E. coli. The zone of inhibition of the precur-
sors is 10, 15, 50 and 34 mm, respectively. The activity of
(C6H5)3SnCl and (CH3)3SnCl is less than their corresponding trior-
ganotin(IV) derivatives of the ligand, whereas as for the other
two precursors the case is reversed. By comparing antibacterial re-
sults of our compounds with the previously reported organotin(IV)
compounds [39,40] show the supremacy of the former.
We thank the Higher Education Commission of Pakistan and the
NSERC (Canada) for financial support.
References
[1] G. Faraglia, S. Sitran, D. Montagner, Inorg. Chim. Acta 358 (2005) 971.
[2] O. Guzel, A. Salman, Bioorg. Med. Chem. 14 (2006) 7804.
[3] P.J. Heard, Prog. Inorg. Chem. 53 (2005) 1.
[4] G.D. Thorn, R.A. Ludwig, The Dithiocarbamates and Related Compounds,
Elsevier, Amsterdam, 1962.
[5] F.W. Sunderman, Ann. Clin. Lab. Sci. 9 (1979) 1.
[6] G.Y. Ding, R.T. Li, Bioorg. Med. Chem. Lett. 15 (2005) 1915.
[7] D.L. Bodenner, P.C. Dedon, P.C. Keng, R.F. Borch, Can. Res. 46 (1986) 2745.
[8] A.H. Neims, D.S. Coffey, L. Hellerman, J. Biol. Chem. 241 (1966) 5941.
[9] S. Khan, S.A.A. Nami, K.S. Siddiqi, J. Organomet. Chem. 693 (2008) 1049.
[10] L.A. Komarnisky, R.J. Christopherson, Nutrition 19 (2003) 54.
[11] S. Ozkirimli, T.I. Apak, M. Kiraz, Y. Yegenoglu, Arch. Pharm. Res. 28 (2005) 1213.
[12] E.R.T. Tiekink, Appl. Organomet. Chem. 22 (2008) 533.
[13] H.P. Chauhan, N.M. Shaik, J. Inorg. Biochem. 99 (2005) 538.
[14] G. Eng, X. Song, Q. Duong, D. Strickman, J. Glass, L. May, Appl. Organomet.
Chem. 17 (2003) 218.
[15] H.D. Yin, S.C. Xue, Appl. Organomet. Chem. 20 (2006) 283.
[16] E.R.T. Tiekink, Appl. Organometal. Chem. 22 (2008) 533.
[17] Z. Rehman, A. Shah, N. Muhammad, S. Ali, R. Qureshi, I.S. Butler, Eur. J. Med.
Chem. 44 (2009) 3986.
[18] Zia-ur-Rehman, A. Shah, N. Muhammad, S. Ali, R. Qureshi, I.S. Butler, J.
Organomet. Chem. 694 (2009) 1998.
[19] W.F.L. Armarego, C. Chai, Purification of Laboratory Chemicals, fifth ed.,
Butterworth, Oxford, 2003.
[20] A.L. Spek, PLATON (Version of October 2007), Program for the Automated
Analysis of Molecular Geometry (A Multipurpose Crystallographic Tool),
University of Utrecht, The Netherlands, J. Appl. Crystallogr. 36 (2003) 7.
[21] A. Rehman, M.I. Choudhary, W.J. Thomsen, Bioassay Techniques for Drug
Development, Harwood Academic Publishers, The Netherlands, 2001, p. 14.
[22] J.M. Vincent, Nature 189 (1947) 850.
The agar tube dilution protocol [21] method was employed to
test the antifungal activities of the synthesized compounds against
four different strains of fungi, and the results are shown in Table 8.
The triorganotin(IV) derivatives are more active than are the chlo-
rodi- and diorganotin(IV) complexes against the fungi tested. In
fact, the activity of the triorganotin(IV) complexes is even more
than that of the standard drug. The cytoplasmic membrane may
be a possible target of action. Interaction of complexes alters the
membrane fluidity [41] and the organism dies because of extensive
K+ leakage. The ligand-salt employed in the present work and the
resulting complexes, 1, 2, 3 and 4, may represent a new class of
drugs that can be administered alone or in combination with oth-
ers in current use, as new formulations for fungal diseases.
The (C4H9)3SnCl, (C6H5)3SnCl, (C6H11)3SnCl and (C4H9)2SnCl2
were tested against Aspergillus nigar and the % inhibition was found
to be 50, 20, 10 and 15, respectively. Compound 2, 4 and 6 are more
active than their respective precursors. Our antifungal results
supersede the findings of Singh et al. for the other organotin com-
pounds [42].
[23] L. Ronconi, L. Giovagnini, C. Marzano, F. Bettío, R. Graziani, G. Pilloni, D.
Fregona, Inorg. Chem. 44 (2005) 1887.
[24] L. Ronconi, C. Maccato, D. Barreca, R. Saini, M. Zancato, D. Fregona, Polyhedron
24 (2005) 521.
[25] F. Bonati, R. Ugo, J. Organomet. Chem. 10 (1967) 257.
[26] T.P. Lockhart, W.F. Manders, E.M. Holt, J. Am. Chem. Soc. 108 (1986) 6611.
[27] S. Shahzadi, S. Ali, K. Wurst, M.N. Haq, Heteroat. Chem. 18 (2007) 664, and
references therein.
[28] T.P. Lockhart, W.F. Manders, E.M. Holts, J. Am. Chem. Soc. 108 (1986) 6611.
[29] R. Willem, A. Bouhdid, M. Biesemans, J.C. Martins, D. Vos, E.R.T. Tiekink, M.
Gielen, J. Organomet. Chem. 514 (1996) 203.
[30] T.S.B. Baul, S. Dhar, S.M. Pyke, E.R.T. Tiekink, E. Rivarola, R. Butcher, F.E. Smith,
J. Organomet. Chem. 633 (2001) 7.
[31] B. Wrackmeyer, Annu. Rep. NMR Spectrosc. 16 (1985) 73.
[32] B. Wrackmeyer, Annu. Rep. NMR Spectrosc. 38 (1999) 203.
[33] A. Tarassoli, T. Sedaghat, B. Neumüller, M. Ghassemzadeh, Inorg. Chim. Acta
318 (2001) 15.
[34] A.W. Addison, T.N. Rao, J. Reedijk, J. van Rijn, G.C. Verschoor, J. Chem. Soc.,
Dalton Trans. (1984) 1349.
[35] M.I. Mohamed-Ibrahim, S.S. Chee, M.A. Buntine, M.J. Cox, R.T. Tiekink,
Organometallics 19 (2000) 5410.
[36] Zia-ur-Rehman, S. Ali, N. Muhammad, A. Meetsma, Acta Crystallogr., Sect. E 63
(2007) m431.
[37] C.M. Thimmaiah, G.T. Chadrappa, W.D. Lloyd, Inorg. Chim. Acta 107 (1985)
281.
[38] D.C. Menezes, F.T. Vieira, G.M. de Lima, J.L. Wardell, M.E. Cortés, M.P. Ferreira,
M.A. Soares, A. Vilas Boas, Appl. Organomet. Chem. 22 (2008) 221.
[39] M. Affan, S.W. Foo, I. Jusoh, S. Hanapi, E.R.T. Tiekink, Inorg. Chim. Acta 362
(2009) 5031.
4. Conclusions
[40] W. Kang, X. Wub, J. Huang, J. Organomet. Chem. 694 (2009) 2402.
[41] Zia-ur-Rehman, N. Muhammad, S. Ali, I.S. Butler, A. Meetsma, M. Khan,
Polyhedron 28 (2009) 3439.
[42] R.V. Singh, P. Chaudhary, K. Poonia, S. Chauhan, Spectrochim. Acta Part A 70
(2008) 587.
The present paper describes the synthesis, characterization and
antimicrobial activities of ten new organotin(IV) 4-(4-methoxy-
phenyl)piperazine-1-carbodithioates. X-ray single crystal study
proved a dimeric and a supramolecular molecular structure for